Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.x

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

Publications

Hiramatsu K, Ishizuka H, Yamasaki M

Bronchiolar disease associated with gold compounds administration in a patient with rheumatoid arthritis.

Modern rheumatology 2005;15;148-52 — 2005 — 148-52

Tomioka R, King TE

Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.

American journal of respiratory and critical care medicine 1997 Mar;155;1011-20 — 1997 Mar — 1011-20

Schwartzman KJ, Bowie DM, Yeadon C, Fraser R, Sutton ED, Levy RD

Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis.

The European respiratory journal 1995 Dec;8;2191-3 — 1995 Dec — 2191-3